Development of Pancreatic Surgery Composite Endpoint (PACE) Enables Lower Sample Sizes and Enhanced Feasibility in Future Trials

Researchers developed and validated a new clinically relevant endpoint, Pancreatic Surgery Composite Endpoint (PACE), for pancreatic surgery. PACE incorporates postoperative pancreatic fistula, post-pancreatectomy hemorrhage, reoperation, and reinterventions. It demonstrated high predictive value for prolonged length of hospital stay (LOS) and mortality in both the development and validation cohorts. PACE allowed for significant reduction in sample sizes and can be effectively used in future prospective trials, offering improved feasibility compared to single outcome measures.